£3.00 SP WILL ARRIVE20 Jul 2020 15:30
"We are all delighted with the trial results announced today. This assessment of SNG001 in Covid-19 patients could signal a major breakthrough in the treatment of hospitalised Covid-19 patients. Our efforts are now focused on working with the regulators and other key groups to progress this potential Covid-19 treatment as rapidly as possible," said Chief Executive Richard Marsden.